Results 211 to 220 of about 22,201 (271)

Testosterone Versus Clomiphene Treatment of Hypogonadism: A Retrospective Analysis in US Veterans

Andrology, Volume 14, Issue 5, Page 1292-1299, July 2026.
ABSTRACT Background Male hypogonadotropic hypogonadism is a complex condition with a multifactorial etiology. Although testosterone replacement therapy (TRT) is the only approved treatment for male hypogonadism, clomiphene citrate (CC) is often used as an off‐label treatment.
Shourya Tadisina, Elizabeth Cristiano, Thomas Wiegmann, Ken Grasing, Betty Drees, Ram Sharma, Mariana Garcia‐Touza   +6 more
wiley   +1 more source

The Effect of Dopaminergic Medication on Impulse Control and Compulsive Behaviour: A Translational Perspective

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 1, July 2026.
ABSTRACT Dopaminergic medication used in disorders like Parkinson's disease (PD) and restless legs syndrome can cause impulsive‐compulsive behaviour (ICB), often with strong negative effects on patients' quality of life. This narrative review presents translational evidence on iatrogenic ICB, taking findings from epidemiological, clinical, neuroimaging
Mirjam Wolfschlag, Elena Espa, Kevin Oliveira Hauer, Jonathan Timpka, Ruben Smith, Per Odin, Maria Angela Cenci, Anders Håkansson   +7 more
wiley   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, Volume 183, Issue 14, Page 3970-3991, July 2026.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Cost-Effectiveness of Treating Hepatitis C in Clients on Opioid Agonist Therapy in Community Pharmacies Compared to Primary Healthcare in Australia. [PDF]

J Viral Hepat
Ginnane JF, Scott N, Radley A, Dillon JF, Hellard M, Doyle J.   +5 more
europepmc   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, Volume 183, Issue 14, Page 3992-4005, July 2026.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, Volume 183, Issue 14, Page 4058-4071, July 2026.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Association between prescribed stimulant medications and overdose among individuals receiving opioid agonist therapy: A retrospective cohort study from British Columbia, Canada. [PDF]

Addiction
Young S, Fairbairn N, Cui Z, Bach P, Mok WY, Budau J, Slaunwhite A, Ti L, Hayashi K, Nolan S.   +9 more
europepmc   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, Volume 183, Issue 14, Page 4022-4047, July 2026.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

Prevalence and Correlates of Reporting a Gabapentin Prescription for Pain Among People Who Use Opioids: A Longitudinal Community‐Recruited Study

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction Gabapentin is widely prescribed off‐label to treat pain. However, there are concerns about the proliferation of medical and non‐medical use, and the potential increased risk of overdose death associated with concurrent opioid use.
Evelyne Marie Piret, Heather Palis, Alexis Crabtree, JinCheol Choi, Kora DeBeck, Kanna Hayashi, Michael R. Law, M.‐J. Milloy   +7 more
wiley   +1 more source